Resources
Immuno-Oncology Journal Club/Trainee Presentations
Fridays at 1:30 pm EST. Via Zoom
May 19, 2023
LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655/ACLY signal, published in Cancer Cell International. October 2022. Presented by Danielle Taray-Matheson
May 12, 2023
Imaging glial activation using [18F]-FEPPA PET post-cranial irradiation (PhD project) presented by Sawyer Badiuk
May 5, 2023
The Effect of Akkermansia muciniphila and Its Outer Membrane Vesicles on MicroRNAs Expression of Inflammatory and Anti‑inflammatory Pathways in Human Dendritic Cells, published in Probiotics and Antimicrobial Proteins. March 2023. Presented by Amanda Liddy.
April 28, 2023
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumorCD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor, published in Immunity. January 2023. Presented by Megan Hong.
April 21, 2023
Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particlesSimultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles, published in Molecular Therapy. March 2023. Presented by Raphael Sanchez-Pupo.
March 3, 2023
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance, published in Cancer Cell. January 2023. Presented by Yeganeh Yousefi.
February 24, 2023
Diet Alters Entero-Mammary Signaling to Regulate the Breast Microbiome and Tumorigenesis, published in Cancer Res. June 2021. Presented by Hasti Gholami.
Feburary 10, 2023
Emerging Biomedical Applications Based on the Response of Magnetic Nanoparticles to Time-Varying Magnetic Fields, published in Annual Review of Chemical and Biomolecular Engineering. April 2021. Presented by Julia Gevaert.
February 3, 2023
Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression, published in Cancer Immunology, Immunotherapy. January 2022. Presented by Danielle Taray-Matheson.
January 27, 2023
Akkermansia supplementation reverses the tumorpromoting effect of the fecal microbiota transplantation in ovarian cancer, published in Cell Report. December 2022. Presented by Amandy Liddy.
December 16, 2022
Non-Invasive imagine of extracellular vesicle. Quo vaditis in vivo, published in ISEV, June 2022. Presented by Oliva Sehl.
December 9, 2022
Non-invasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy, published in J Clin Invest. July 2022. Presented by Rafael Sanchez Pupo.
December 2, 2022
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Published in Cancer Cell, March 2022. Presented by Megan Hong.
November 18, 2022
IL-27 improves adoptive CD89+ T cells' antitumor activity via enchancing cell survival and memory T cell differentiation. Published in Cancer Science-Wiley, November 2021. Presented by Lara Gerhardt
May 27, 2022
Tracking adoptive T cell immunotherapy using magnetic particle imaging. Published in Nanotheranostics, Vol. 5. Presented by Julia Gevaert.
May 13, 2022
Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Published in Immunity, December 2021. Presented by Lara Gerhardt.
April 29, 2022
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Published in Immunity, February 2022. Presented by Marwa Said
April 22, 2022
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Published in Nature Communications, March 2022. Presented by Megan Hong
April 8, 2022
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Published in Science, August 2020. Presented by Yeganeh Yousefi
March 11, 2022
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. Published in N.Eng.J of Med, June 2022. Presented by Jasna Deluce
March 4, 2022
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Published in Nature, January 2021. Presented by Rafael E. Sánchez Pupo.
February 25, 2022
CD39 + HBVs-CAR T and personalized tumor reactive CD8+ T cells exhibit potent anti-HCC activity. Published in Molecular Therapy, May 2022. Presented by Lara Gerhardt.
February 18, 2022
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. Published International Journal of Radiation Oncology, June 2021. Presented by Sawyer Badiuk.
February 11, 2022
In vivo imaging of nanoparticle-labeled CAR T cells. Published in PNAS, January, 2022
December 4, 2021
Lack of CD8+ T cell effector differentiation duringpriming mediates checkpoint blockade resistance in non–small cell lung cancer. Published in Science Immunology. Presented by Lara Gerhardt.
November 26, 2021
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Published in Science Translational Medicine. Presented by Melissa Evans.
November 19, 2021
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Published in Immunotherapy. Presented by Jasna Deluce.
November 12, 2021
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Published in Cancer Research. Presented by Olivia Sehl.
October 29, 2021
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. Published in The Journal of Clinical Investigation". Presented by Sawyer Badiuk.
October 22, 2021
18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. Published in Nuclear Medicine. Presented by Rafael E. Sanchez Pupo.
October 1, 2021
An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Published in Nature, September 2021. Presented by Lara Gerhardt.
September 24, 2021
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against sold tumors. Published in Science Translational Medicine, August 2021. Presented by Megan Hong.
June 25, 2021
Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Published in International Journal of Molecular Science, May 2021. Presented by Sawyer Badiuk.
May 28, 2021
LIMIT is an immunogenic IncRNA in cancer immunity and immunotherapy.Published in Nature, May 2021. Presented by Yili Xu.
May 14, 2021
Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. Published in Journal for ImmunoTherapy of Cancer, 2021. Presented by Megan Hong.
May 7, 2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells by Nathan Singh et al. published in Nature Medicine, 2021. Presented by Hita Rishi.
April 23, 2021
Sequence of aPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.” by Wei et al. and was published in Science Immunology. Presented by Lara Gerdhart. Supplementary Material
April 9, 2021
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, 2019, presented by Dr. Jasna Deluce.
March 26, 2021
Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer, The Journal of Nuclear Medicine, February 2021, presented by Dr. Ting-Yim Lee.
March 19, 2021
Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nature Communication, March 2021, presented by Lara Gerhardt.
March 12, 2021
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer, PNAS, November 2019, presented by Yili Xiu.
March 5, 2021
FMT + IO Trials. Dr. Mithunah Krishnamoorthy to present two recently published papers in Science, February 2021.
February 26, 2021
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Science Direct, August 2018 presented by Melissa Evans.
February 19, 2021
Chitosan/ÿ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. PubMed, October 2020 presented by Sawyer Badiuk
February 12, 2021
Cancelled due to the IO symposium
February 5, 2021
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018 presented by Dr. Jasna Deluce.
January 29, 2021
Personal neogantigen vaccines induce persistent memory T cell responses and epitope spreading in patients and melanoma. Nature Medicine, 2021 presented by Dr. Mithunah Krishnamoorthy.
January 22, 2021
SHP2 blockade enhances anti-tumor immunity via tumor cell-intrinsic and extrinsic mechanisms, Scientific Reports volume 11, Article number: 1399 (2021) presented by Yili Xu
January 15, 2021
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade, Cell Death & Disease volume 11, Article number: 1062 (2020) presented by Hita Rishi
December 11, 2020
Imaging of T-cells and their responses during anti-cancer immunotherapy, Theranostics 2019, Vol. 9, Issue 25 presented by Dr. Ting Lee
December 4, 2020
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects, Nature Immunology, https://doi.org/10.1038/s41590-020-00818-9 presented by Dr. Mithunah Krishnamoorthy
November 27, 2020
Enhanced CAR-T activity against established tumors by polarizing human T cells to secreteinterleukin-9, Nature Communications, (2020) 11:5902 https://doi.org/10.1038/s41467-020-19672 Presented by Yili Xu
November 13, 2020
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer, Nature, https://doi.org/10.1038/s41586-020-2911-7, presented by Mikal El-Hajjar
November 6, 2020
Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway, OncoImmunology, 9:1, 1824643, DOI: 10.1080/2162402X.2020.1824643, presented by Lara Gerhardt
